MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses
Jia Ruan(Cornell University), Peter Martin(Northwestern University), Bijal Shah(Boston College), Michael Sigouros(Cornell University), John N. Allan(Cornell University), Bhavneet Bhinder(Cornell University), John P. Leonard(New York University), Caitlin Gribbin(Cornell University), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Olivier Elemento(Cornell University), Wayne Tam(Cornell University), Brittany Hobbie(Cornell University), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Zhengming Chen(Population Council), Giorgio Inghirami(Cornell University), T. Sahni(Cornell University), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Melinda Harbhajan(Cornell University), Kami J. Maddocks(The Ohio State University)
Cited by 7
Related Papers
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Stroke in China: advances and challenges in epidemiology, prevention, and management
|The Lancet Neurology|2019|1.6k